Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?

about

Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?

Item

http://www.wikidata.org/entity/Q53804314

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Does outcome of second salvage ...... rst or second salvage therapy?

@en

Does outcome of second salvage ...... rst or second salvage therapy?

@nl

type

Item

label

Does outcome of second salvage ...... rst or second salvage therapy?

@en

Does outcome of second salvage ...... rst or second salvage therapy?

@nl

prefLabel

Does outcome of second salvage ...... rst or second salvage therapy?

@en

Does outcome of second salvage ...... rst or second salvage therapy?

@nl

P1476

Does outcome of second salvage ...... rst or second salvage therapy?

@en

P2093

Daisuke Araki

http://www.w3.org/2001/XMLSchema#string

Elihu H Estey

http://www.w3.org/2001/XMLSchema#string

Pamela S Becker

http://www.w3.org/2001/XMLSchema#string

Roland B Walter

http://www.w3.org/2001/XMLSchema#string

Vicky Sandhu

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Treatment of relapsed and refractory acute myelogenous leukemia.

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.

Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

Acute myeloid leukemia in the elderly: do we know who should be treated and how?

The past and future of CD33 as therapeutic target in acute myeloid leukemia.

Outcome of patients with acute myelogenous leukemia after second salvage therapy.

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

P304

1205-1207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2015.1079316

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Megan Othus

P577

2015-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26694896

http://www.w3.org/2001/XMLSchema#string